Before the clinical advent of TKIs, α-interferon (IFN) or IFN-based therapies were the treatment of choice for CML, and hydroxyurea (HU) also played a major clinical role [8,9]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.